Sodium/glucose cotransporter 2 inhibitor treatment of type 2 diabetes treatment of obesity

Drugs of the Future

Volumn 36, Issue 5, 2011, Pages 351-357

  Chao, Edward C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CANAGLIFLOZIN; GLUCOSE; GLUCOSE TRANSPORTER 2; INCRETIN; INSULIN; METFORMIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA;

AREA UNDER THE CURVE; DIABETES MELLITUS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; EDEMA; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; WEIGHT GAIN;

EID: 84952976440     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.05.1590789     Document Type: Review

References (27)

1. Abdel-Magid, A.F., Chisholm, M., Mehrman, S. et al. (Janssen Pharmaceutica NV; Mitsubishi Tanabe Pharma Corp.). Process for the preparation of compounds useful as inhibitors of SGLT. CN 101801371, EP 2200606, JP 2010539092, WO 2009035969.
2. Ellsworth, B., Washburn, W.N., Sher, P.M., Wu, G., Meng, W. (Bristol-Myers Squibb Co.). C-Aryl glucoside SGLT2 inhibitors and method. EP 1506211, JP 2005531588, JP 2009275050, US 2002137903, US 6515117, WO 2003099836.
3. Nomura, S., Ueta, K., Kawanishi, E. (Mitsubishi Tanabe Pharma Corp.). Novel compounds having inhibitory activity against sodium-dependant transporter. EP 1651658, JP 2007518683, JP 2008266328, WO 2005012326.
4. Nomura, S., Sakamaki, S., Hongu, M. et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010, 53(17): 6355-60.
5. Filliers, W.F.M., Broeckx, R.L.M., Nieste, P.H.J., Hatsuda, M., Yoshinaga, M., Yada, M. (Janssen Pharmaceutica NV; Mitsubishi Tanabe Pharma Corp.). Process for the preparation of compounds useful as inhibitors of SGLT. US 2010099883, WO 2010043682.
6. International Diabetes Foundation Diabetes Atlas. http://www. diabetesatlas.org/content/foreword. Accessed December 4, 2010.
7. Kaiser, N., Leibowitz, G., Nesher, R. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2003, 16(1): 5-22. (Pubitemid 37259087)
8. Porte, D. Jr. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diabetes Metab Res Rev 2001, 17/3): 181-8.
9. Inzucchi, S.E. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002, 287(3): 360-72. (Pubitemid 34256388)
10. Buse, J.B., Henry, R.R., Han, J., Kim, D.D., Fineman, M.S., Baron, A.D.; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27(11): 2628-35. (Pubitemid 39441462)
11. Wright, E.M. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001, 280(1): F10-18.
12. Wright, E.M., Turk, E. The sodium/glucose cotransport family SLC5. Pflugers Arch 2004, 447(5): 510-8. (Pubitemid 38241437)
13. Lee, Y.J., Han, H.J. Regulatory mechanisms of Na+/glucose cotransporter in renal proximal tubule cells. Kidney Int Suppl 2007, 106: S27-35. (Pubitemid 47172558)
14. Rahmoune, H., Thompson, P.W., Ward, J.M., Smith, C.D., Hong, G., Brown, J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005, 54(12): 3427-34. (Pubitemid 43334332)
15. Rossetti, L., Smith, D., Shulman, G.I., Papachristou, D., DeFronzo, R.A. Correction of hyperglycemia with phlorizin normalizes tissues sensitivity to insulin in diabetic rats. J Clin Invest 1987, 79(5): 1510-5. (Pubitemid 17099657)
16. th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 25-29, Orlando) 2010] 2010, 59(Suppl. 1): Abst 77-OR.
17. th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 25-29, Orlando) 2010] 2010, 59(Suppl. 1): Abst 564-P.
18. thAnnu Meet Sci Sess Am Diabetes Assoc (ADA) (June 25-29, Orlando) 2010] 2010, 59(Suppl. 1): Abst 567-P.
19. th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 25-29, Orlando) 2010] 2010, 59(Suppl. 1): Abst 568-P.
20. th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 25-29, Orlando) 2010] 2010, 59(Suppl. 1): Abst 76-OR.
21. Sha, S., Devineni, D., Ghosh, A. et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose-dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011, Epub ahead of print.
22. thAnnu Meet Sci Sess Am Diabetes Assoc (ADA) (June 25-29, Orlando) 2010] 2010, 59(Suppl. 1): Abst 646-P.
23. Bays, H. From victim to ally: The kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 2009, 25(3): 671-81.
24. Hediger, M.A., Rhoads, D.B. Molecular physiology of sodium-glucose cotransporter. Physiol Rev 1994, 74(4): 993-1026.
25. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetología 1985, 28(7): 412-9. (Pubitemid 15018832)
26. Wallace, T.M., Levy, J.C., Matthews, D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27(6): 1487-95. (Pubitemid 38680001)
27. Abdul-Ghani, M., DeFronzo, R.A. Inhibition of renal glucose reabsorption: A novel strategy for achieving glucose control in type 2 diabetes. Endocr Pract 2008, 14(6): 782-90.